Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Rectal Cancer
•
Medical Oncology
•
Colorectal Cancer
•
NCI-CCC Tumor Board Question
•
NCI-CCC GI Tumor Board Question
•
Memorial Sloan Kettering
For patients with rectal cancer being treated along PROSPECT paradigm, would you extrapolate from the IDEA literature and offer 3 months of CAPOX neoadjuvantly, without adjuvant therapy?
Answer from: Medical Oncologist at Community Practice
I would! I did it in a recent patient.
Sign in or Register to read more
20161
Related Questions
In patients with T1 anal squamous cell cancer status post local excision with a close margin, would you recommend close observation or adjuvant concurrent chemoradiation?
In patients with cholangiocarcinoma who qualify for HAIP therapy, would you recommend treating with chemotherapy and immunotherapy?
Is there any circumstance where you would consider bevacizumab in patients with locally advanced colorectal cancer with rectouterine fistula?
Which patients, if any, treated according to PROSPECT for an early stage rectal cancer, would you offer surveillance if they achieved cCR after neoadjuvant chemotherapy?
Is there a role of adjuvant or systemic therapy for patients with resected stage I colon cancer with subsequent local recurrence S/P a second resection and now has NED?
Would you ever consider foregoing surveillance CT scans for resected stage II or III colon cancer in favor of circulating ctDNA assays?
Are there any adverse risk factors in stage I colon cancer that would warrant ctDNA testing?
Would you change treatment approach for rectal cancer with an associated intussusception?
What systemic therapy would you use in T3N1M1 MMR proficient rectal cancer with solitary liver lesion when going for curative intent (chemo>short course RT> resection of primary and liver met)?
How was treatment response assessed on the PROSPECT trial?